PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside-Reference-Cited by-同舟云学术

PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside

Published:2022-05-20 Issue:3 Volume:8 Page:690-698
ISSN:2057-4347
Container-title:Clinical and Experimental Dental Research
language:en
Short-container-title:Clinical & Exp Dental Res

Author:

Nocini Riccardo¹,Vianini Matteo²,Girolami Ilaria³,Calabrese Luca⁴,Scarpa Aldo⁵,Martini Maurizio⁶,Morbini Patrizia⁷,Marletta Stefano⁵,Brunelli Matteo⁵,Molteni Gabriele¹,Parwani Anil⁸,Pantanowitz Liron⁹,Eccher Albino¹⁰^ORCID

Affiliation:

1. Otolaryngology—Head and Neck Surgery Department University and Hospital Trust of Verona Verona Italy

2. Department of Otolaryngology Villafranca Hospital Verona Italy

3. Division of Pathology Central Hospital Bolzano Bolzano Italy

4. Division of Otorhinolaryngology, Central Hospital Bolzano Bolzano Italy

5. Department of Diagnostics and Public Health, Section of Pathology University of Verona Verona Italy

6. Catholic University‐Fondazione Policlinico Universitario “A. Gemelli” IRCCS Rome Italy

7. Department of Molecular Medicine Unit of Pathology, University of Pavia and Foundation IRCCS Policlinico S. Matteo Pavia Italy

8. Department of Pathology, Wexner Medical Center Ohio State University Columbus Ohio USA

9. Department of Pathology & Clinical Labs University of Michigan Ann Arbor Michigan USA

10. Department of Pathology and Diagnostics University and Hospital Trust of Verona Verona Italy

Publisher

Wiley

Subject

General Dentistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cre2.590

Reference52 articles.

1. High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments

2. Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

4. Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study

5. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on “Exploring PD-1 methylation in oral cancer: A crucial frontier in immunotherapy”;Oral Oncology Reports;2024-09

2. Harnessing programmed death-ligand 1 as a prognostic marker in OSCC: Challenges and opportunities in the era of immunotherapy;Oral Oncology Reports;2024-09

3. Emerging therapeutic targets in oral squamous cell carcinoma: Insights from genetic alterations;Oral Oncology Reports;2024-06

4. New Strategies for Macrophage Re-Education in Cancer: An Update;International Journal of Molecular Sciences;2024-03-18

5. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis;The Journal of Nutritional Biochemistry;2024-03